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missions. Often it is mentioned that in order to obtain unbiased
estimates based on indirect comparisons the distribution of char-
acteristics of the patients included in the different trials needs to
be similar, as well as the study design. By means of directed
acyclic graphs (DAGs), which are often used in epidemiology for
inferences, it is explained that indirect and mixed treatment
comparisons are biased when differences in patient characteris-
tics and trial design do act as an effect modiﬁer of the treatment
effect. Furthermore, the graphs can be used to differentiate
between heterogeneity, selection, and confounding bias. DAGs
for indirect comparisons of RCTs are compared with DAGs for
head-to-head randomized designs and meta-analysis of RCTs.
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OBJECTIVES: Per member per month (PMPM) utilization rates
are commonly reported in the medical literature to compare
differences in costs and other outcomes across various health care
technologies and interventions. A limitation of PMPM estimates
is that a conﬁdence limit around the point estimate is not obvious
or available from standard statistical software. Our objective is
to demonstrate various methods of calculating conﬁdence inter-
vals for PMPM utilization rates. METHODS: Several methods
were used to estimate conﬁdence intervals surrounding PMPM
estimates including Fieller’s method and Monte-Carlo (MC)
simulation. Women with at least one prescription ﬁll for alendr-
onate, risedronate, or ibandronate during 2006 in a large
managed care data set were used as a sample to generate PMPM
estimates and 95% conﬁdence intervals for bisphosphonate drug
cost, all hospitalization cost, hospital days, and number of hos-
pital admissions during the calendar year of 2006. RESULTS:
There were 34,675 women in our sample. The PMPM estimate
of bisphosphonate drug cost was $23.48. The 95% conﬁdence
intervals generated by the Fieller and MC methods were ($23.21,
$23.75) and ($23.45, $23.87), respectively. The PMPM hospi-
talization cost was $242.28: Fieller and MC 95% conﬁdence
intervals were ($221.53, $263.03) and ($227.74, $259.99),
respectively. The PMPM estimate of hospital days was 0.108
days: Fieller and MC 95% conﬁdence intervals were (0.098,
0.118) and (0.100, 0.116), respectively. The PMPM point esti-
mate for number of hospital admissions was 0.0137: Fieller
and MC 95% conﬁdence intervals were (0.0131, 0.0142) and
(0.0133, 0.0142), respectively. CONCLUSION: The Fieller and
MC simulation methods produced similar conﬁdence intervals
for PMPM estimates for each of the outcomes of interest. Use of
these methods would improve the utility of PMPM point esti-
mates in comparing health care technologies.
PMC4
THE ADOPTION AND DIFFUSION OF COST-EFFECTIVENESS
ACCEPTABILITY CURVES IN PUBLISHED ECONOMIC
EVALUATIONS
Greenberg D1, Cohen JT2, Neumann PJ2
1Ben-Gurion University of the Negev, Beer-Sheva, Israel, 2Tufts-New
England Medical Center, Boston, MA, USA
Cost-effectiveness acceptability curves (CEACs) plot the prob-
ability that one treatment is more cost-effective than another, as
a function of a societal threshold willingness to pay for addi-
tional units of efﬁcacy (e.g., life-year or QALY gained). OBJEC-
TIVES: To assess the adoption and diffusion rates of CEACs
within the ﬁeld of economic evaluations. METHODS: We used
the Tufts-New England Medical Center registry of 620 published
cost-effectiveness analyses (CEA), presenting an original cost/
QALY ratio from 2002–2005 (http://www.tufts-nemc.org/
cearegistry/). For each CEA we recorded the year of publication,
journal’s name, study origin (country), and a subjective assess-
ment of overall study quality ranging from 1 (low) to 7 (high).
We used univariate analyses (chi-square and t-test), to assess
differences in CEAC use by year of publication, study origin and
quality. We also compared practices in journals publishing a
high-volume (n  10) versus low-volume (n < 10) of CEAs
during the study period. We used multivariable logistic regression
to identify factors predicting CEAC use. RESULTS: Approxi-
mately one ﬁfth (20.2%) of CEAs presented a CEAC. The adop-
tion of CEACs has increased over time from 5.3% (2002) to
30.4% (2005) (p < 0.0001). Studies using CEAC were of higher
quality (4.6  1.0 vs.4.1  0.9; p < 0.0001) and more prevalent
in high-volume journals (30.7% vs. 16.4%; p < 0.0001). CEACs
were more frequently used in UK studies (48.8%) versus studies
from Sweden (24.1%), The Netherlands (17.9%), United States
(11.7%), and Canada (9.1%). Signiﬁcant predictors for using
CEACs were study quality (OR 1.96; 95% CI-1.53–2.51), pub-
lication in a high-volume journal (OR 1.85; 95% CI-1.18–2.89),
and year of publication. CONCLUSIONS: CEACs have been
rapidly adopted, especially among UK-based investigators. If
CEACs turn out to be a useful tool to decision makers, this trend
is encouraging, but means to achieve more rapid deployment
should be identiﬁed.
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OBJECTIVE: To review and critically evaluate published cost-
utility analysis (CUA) research on pharmaceuticals for the
past three decades. METHODS: We examined data from the
Tufts-NEMC Cost-Effectiveness Analysis Registry www.tufts-
nemc.org/cearegistry), which contains detailed information on
over 1100 CUAs and 3000 cost-utility ratios (in $US2005) pub-
lished from 1976–2005. RESULTS: Of 1164 CUAs published
through 2005, 518 (44.5%) pertain to pharmaceuticals. The
proportion of all CUAs that focus on pharmaceuticals increased
from 32% prior to 1990 to 48% from 1990–2005. U.S.-based
investigators account for 53.6% of the total (47.5% of pharma-
ceutical studies), though the relative proportion of US-based
studies has decreased over time. The U.K.’s share of total pub-
lished CUAs increased from 7% in 1990 to 18% in 2005. The
quality of study (as measured by a subjective 1–7 scale) did not
differ by type of sponsorship (4.4 for industry vs. 4.55 for non-
industry, p = 0.44). The leading journals for publishing pharma-
ceutical CUAs were Pharmacoeconomics (58 CUAs), Ann Intern
Med (47), Int J Technol Assess Health Care (37), JAMA (34) and
Am J Med (25). About 38% of pharmaceutical CUAs were
sponsored by pharmaceutical companies, 27% by non-industry
sources (and in 35% the source of funding could not be deter-
mined). Pﬁzer (26), Norvatis (25), Schering Plough (23), GSK
(21) and Roche (19) have funded the most pharmaceutical CUAs.
The median of 1055 pharmaceutical CE ratios is $26,000/QALY
and is lower for industry vs. non-industry funded studies
(p = 0.004). In multivariate analysis adjusting for factors such as
sponsor type, pharmaceutical CE ratios are similar to others—
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